Edition:
United States

Neuren Pharmaceuticals Ltd (NEU.AX)

NEU.AX on Australia Stock Exchange

0.08AUD
27 Mar 2017
Change (% chg)

$-0.00 (-2.53%)
Prev Close
$0.08
Open
$0.08
Day's High
$0.08
Day's Low
$0.08
Volume
1,091,549
Avg. Vol
1,784,598
52-wk High
$0.12
52-wk Low
$0.04

Latest Key Developments (Source: Significant Developments)

Neuren Pharmaceuticals says IRSF confirms financial support for Neuren's clinical trials
Monday, 12 Oct 2015 06:48pm EDT 

Neuren Pharmaceuticals:Says that the International Rett Syndrome Foundation (Rettsyndrome.org) has made a financial commitment of up to US$1 million, to continue its support of Neuren's clinical trials of trofinetide for the treatment of Rett syndrome.  Full Article

Neuren Pharmaceuticals updates on progress in orphan drug programs
Wednesday, 29 Jul 2015 02:16am EDT 

Neuren Pharmaceuticals Ltd:Orphan drug designation for trofinetide in both rett syndrome and fragile x syndrome recommended by European medicines agency.Enrolment completed in fragile x phase 2 clinical trial; top-line results expected in December 2015.Says anticipates that the European commission will provide formal confirmation of these designations in August 2015.Says to propose to FDA a design for a single phase 3 clinical trial to support a new drug application for rett syndrome.  Full Article

Neuren Pharmaceuticals Limited announces issue of shares
Monday, 1 Jun 2015 05:13am EDT 

Neuren Pharmaceuticals Limited:Issues 7,816,667 Ordinary Shares at $0.0162 per share for a consideration of $126,630.  Full Article

Neuren Pharmaceuticals Limited issues ordinary shares
Wednesday, 22 Apr 2015 03:53am EDT 

Neuren Pharmaceuticals Limited:Issues 7,653,349 fully paid ordinary shares for a consideration of $123,281.  Full Article

More From Around the Web

BRIEF-Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric rett syndrome

* Neuren's Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric rett syndrome Source text for Eikon: